Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8096462 | 1.00 | CYP2C19 (0.52) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL8100779 | 0.88 | TSHR (0.52) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL14669652 | 0.79 | ALDH1A1 (0.55) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL8100774 | 0.76 | CYP2C19 (0.50) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL3577280 | 0.76 | CFD (0.48) | CYP2C19TSHRCYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL3573635 | 0.75 | TSHR (0.49) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL3573633 | 0.75 | TSHR (0.49) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL8102978 | 0.74 | TSHR (0.61) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL3570922 | 0.74 | CFD (0.41) | CYP2C19TSHRCYP2C9ALDH1A1KMT2A | |
| SCHEMBL12320479 | 0.74 | ALDH1A1 (0.52) | CYP2C19TSHRCYP2C9ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | CYP2C19 3214/4885TSHR 2691/4885CYP2C9 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.